• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CeriBell (CBLL) Launches Delirium Monitor As Results Test Whether The Stock Already Looks Pricey

    Simply Wall St·11/04/2026 13:16:12
    Listen to the news

    CeriBell (CBLL) has just paired fresh financials with a new product launch, as its AI-driven delirium monitoring solution reaches the market alongside third quarter and year to date earnings updates.

    CeriBell’s recent product launch and earnings update have landed in the middle of a powerful run, with the share price at $28.27 and a 90 day share price return of 54.9% feeding into a 1 year total shareholder return of 139.98%. This suggests momentum has been building as investors reassess both growth potential and execution risks around its AI driven brain monitoring platform.

    Scan beyond CeriBell and review hand-picked ICU and hospital technology peers through the 34 healthcare AI stocks that target similar AI-driven opportunities in patient monitoring and clinical decision support.

    After a move like this, the valuation gap starts to matter. With CeriBell trading just below analyst targets, how far does fair value really sit from today’s price range?

    Preferred Price-to-Sales Multiple of 10.6x: Is it justified?

    CeriBell’s share price strength has pushed its key valuation yardstick well above typical levels, with the stock trading on a P/S ratio of 10.6x while analysts place their average price target only slightly above the current $28.27 level.

    The P/S ratio compares the market value of the equity to the last twelve months of revenue, which matters a lot for a healthcare technology business that is still loss making. For CeriBell, investors are effectively paying 10.6 times its $101.964m of annual sales for exposure to its acute care EEG platform and AI driven monitoring tools.

    That pricing looks heavy when lined up against peers and estimated “fair” levels. CeriBell’s 10.6x P/S is more than double the peer average of 4.6x and materially above the US Medical Equipment industry average of 2.8x. The Fair Price-to-Sales Ratio is estimated at 7.4x, which is a level the market could move towards if expectations ease.

    Explore the SWS fair ratio for CeriBell.

    Result: Price-to-Sales of 10.6x (OVERVALUED)

    Still, CeriBell’s reliance on a single product family and continuing net losses of $65.997m leave little room if hospital demand or reimbursement trends disappoint.

    Find out about the key risks to this CeriBell narrative.

    Next Steps

    Reading through CeriBell’s mix of strong momentum and rich pricing, you can either lean into the excitement or question how much is already reflected. Move quickly, examine the numbers carefully, and weigh both sides of the story through the 1 key reward and 2 important warning signs.

    Looking for more investment ideas beyond CeriBell?

    If CeriBell has sharpened your focus on where capital goes next, do not stop here. Broader opportunity sits with the right watchlist and a disciplined process.